Loading...

DAWN DAY ONE BIOPHARMACEUTICALS INC US FDA Inspections 8-K Filing

DY N

DWN

DAY ONE BIOPHARMACEUTICALS INC

(DAWN)

2026 8-K

Amendment Filing

Merger Agreement Signed

Positive Regulatory Update

Financial Results Announced

Financial Update

Merger Agreement Report

Financial Update

Stock Option Repricing

Financial Statements

Financial Statements

Financial Results

Financial Update

Management Change

Financial Results

Earnings Reports

Securities Purchase Agreement

License Agreement with Ipse...

License Agreement with MabC...

Corporate Presentation Upda...

Annual Meeting of Stockholders

Earnings Reports

FDA Approval for OJEMDA

Amendment to License Agreement

Appointment of New Directors

Participation in J.P. Morga...

Code Amendments

Phase 2 Trial Results Publi...

Dismissal and Appointment o...

Financial Results Announcement

FDA Accepts NDA for Tovoraf...

Clinical Data and NDA Submi...

Financial Results Announcement

Amendment and Annual Meeting

Corporate Presentation Upda...

Underwriting Agreement

Suspension of Prospectus

Clinical Data Update

Financial Results and Manag...

Poster Presentation

Financial Results Announcement

Amendment to Bylaws

Announcement of Trial Data ...

External Links:

On March 2, 2026, Day One Biopharmaceuticals, Inc. announced that Ipsen Pharma received a positive opinion for the marketing authorization of OJEMDA for treating pediatric low-grade glioma. The company holds an exclusive license with Ipsen to commercialize this drug outside the U.S.

AI Assistant

DAY ONE BIOPHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.